Biodesix Inc. (BDSX) Tops Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls more than 3% on weaker global demand outlook and US crude buildup
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Biodesix Announces Second Quarter 2022 Results and Highlights
August 4, 2022 6:00 AM EDTSecond quarter 2022 core Lung Diagnostic revenue of $7.3 million increased 52% over the comparable period in 2021;
Received Medicare coverage for the Nodify CDT® Lung Nodule Test;
Announced strategic arrangements during the quarter (Royal Philips, Memorial Sloan Kettering Cancer Center and Bio-Rad);
Reaffirm 2022 revenue outlook of between $37.5 million and $39.5 million;
Conference Call and Webcast Today at 8:00 a.m. ET
BOULDER, Colo.--(BUSINESS... More
